Lupin Reports Strong Q4 with Revenue Up 31.9% on Acquisitions

Lupin Ltd announced strong fourth-quarter results for fiscal year 2026, with consolidated revenue reaching ₹7,474.66 crore. This represents a 31.90% increase compared to the same period last year. Net profit for the quarter was ₹1,468.67 crore.

For the full fiscal year ended March 31, 2026, the company’s consolidated revenue grew 23.12% to ₹27,958.03 crore. This growth was significantly boosted by strategic acquisitions made during the year, including Renascience Pharma in the UK and VISUfarma B.V. in the Netherlands. These moves expanded Lupin's presence in key European markets.

Reflecting its profitability, Lupin's board has recommended a dividend of ₹18 per share.

Investors will note key financial challenges. The company has set aside a significant provision of ₹581.69 crore for ongoing antitrust litigation matters. Furthermore, consolidated borrowings, encompassing both current and non-current debt, increased over the fiscal year from ₹50,766.5 million to ₹59,102.0 million.

Lupin's 23.12% annual revenue growth for FY26 surpassed that of peers like Sun Pharmaceutical Industries Ltd (around 12%) and Dr. Reddy's Laboratories Ltd (around 9%). Like Lupin, these companies are also pursuing growth through mergers and acquisitions and expanding their global reach.

Key areas to monitor going forward include the successful integration of the newly acquired European businesses, the resolution of the antitrust litigation, and management's strategy for managing the company's debt levels. Performance in major markets like the US and Europe will also be crucial.